Women's Health Approved Deal Benchmarks — Ex-US

Understanding Women's Health Deal Benchmarks at Approved

Approved Women's Health licensing deals in Ex-US territory command a median upfront payment of $1.1B, with values ranging from $766M at the low end to $1.4B for premium assets. These benchmarks reflect the risk-adjusted value of clinical-stage assets in the women's health therapeutic area, where development costs, competitive dynamics, and market potential all factor into deal pricing.

Total deal values — including milestones for development, regulatory, and commercial achievements — range from $2.3B to $3.3B, with a median of $2.8B. Royalty rates for women's health assets at this stage typically fall between 12.4% and 21.3% of net sales, reflecting the balance between licensor value contribution and licensee commercialization investment.

The Ex-US territory applies a 0.45x multiplier to base deal economics. This accounts for market size, regulatory complexity, pricing environment, and competitive landscape differences across geographies. Licensors negotiating ex-us rights should calibrate upfront expectations and milestone structures accordingly.